Allergan's Pipeline is Strong Says Pfizer | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Pfizer, wending toward a record-setting $160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry insiders.


Chief among Allergan's investigational drugs is rapastinel, a treatment for depression, followed by the gastrointestinal drug relamorelin, a uterine fibroid therapy called Esmya and a Phase II migraine treatment acquired from Merck.